Abstract
Type 2 diabetes mellitus (T2DM) in Mexico is a public health problem due to its high prevalence (in 2020 15.7%) and a continuing healthcare challenge. For Mexico, adding new and effective treatments is crucial to ensure that healthcare resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly Semaglutide versus available GLP-1 RA, SGLT-2 and DPP-4i therapies in Mexico, for the treatment of patients with type 2 diabetes mellitus with inadequate glycaemic control.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
